On 16 October 2023, Silo Pharma announced positive data for the effects of SPU-21 in inflamed human synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
Preclinical data from fresh human tissue
“The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides’ preferential interaction with the inflamed synovial tissue for disease-suppressive effects. We look forward to our next data readout for SPU-21 by the end of the year or early 2024.”
Read more https://ir.silopharma.com/news-releases/
About our Human Tissue Assays
Our clinical network, growing since 2002, provides ethically approved access to biospecimens for use in our research laboratories in the US and UK, where we have worked on over 1,000 potential new drugs to evaluate their effects in humans. We offer organotypic assays across a wide range of tissue types from both healthy and diseased tissues, covering diseases such as IBD, psoriasis, psoriasis, atopic dermatitis, COPD, asthma, hypertension, and heart failure. We can also offer comparative studies across species to better understand the translation of animal data to humans.
